Oxford University and proteomics company announce partnership
21 Mar 2016 by Evoluted New Media
Oxford University has agreed an agreement with SomaLogic, a proteomics firm, for use of their products for research.
Oxford University has agreed an agreement with SomaLogic, a proteomics firm, for use of their products for research.
The deal will see SomaLogic’s SOMAmer reagents and SOMAscan assay technologies to discover and collect protein biomarkers for a range of clinical conditions. A SOMAscan assay service laboratory will also be built at Oxford as part of the agreement.
Professor Simon Lovestone, from Oxford University, said: “This agreement is a model for how we can bring together the best of industry, academia and the National Health Service to improve healthcare outcomes for patients in the UK and beyond. SomaLogic will benefit from access to Oxford's world-leading research to develop and refine its products, while we will benefit from access to technology that can enhance what we do.”
The SOMAscan assay uses more than 1,300 SOMAreagents, protein binding reagents that combine monoclonal antibodies and aptamers, to measure proteins of varying concentrations in samples. The information provided by the SOMAscan will be used in Oxford’s Big Data Institute, which analyses large data sets to improve detection, treatment and prevention of a range of conditions.
George Freeman MP, Life Science Minister said SomaLogic’s investment in Oxford University was an excellent example of unique life sciences offering.
This was echoed by Byron Hewett, SomaLogic’s CEO, “The massive data that will be generated from this agreement should rapidly lead to new applications of our technologies to the clinical diagnosis and management for many diseases and conditions.”